JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, today announced the initiation of a Phase II clinical trial on schizophrenic patients for the maximal tolerated dose determination of BL-1020. BL-1020 is a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.
